Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
Why now
Thesis: Pipeline news with no listed ticker
Catalyst to watch: Enrollment and interim data
Main risk: Phase 3 failure risk remains
Why it matters
A trial expansion is a pipeline milestone but the issuer is not in the covered ticker set.
Details
SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology,...
Sources
- prnewswire · 2026-09-28 00:00 UTC